Catherine Moukheibir Sells 44,426 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Director Catherine Moukheibir sold 44,426 shares of the stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $6.36, for a total value of $282,549.36. Following the completion of the sale, the director now directly owns 84,207 shares in the company, valued at $535,556.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Ironwood Pharmaceuticals Price Performance

Ironwood Pharmaceuticals stock opened at $6.25 on Wednesday. Ironwood Pharmaceuticals, Inc. has a 12-month low of $5.76 and a 12-month high of $15.70. The stock has a market capitalization of $978.31 million, a PE ratio of -0.92 and a beta of 0.51. The firm has a 50 day simple moving average of $7.24 and a 200-day simple moving average of $10.10.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.20). Ironwood Pharmaceuticals had a negative net margin of 254.41% and a negative return on equity of 28.45%. The firm had revenue of $74.90 million for the quarter, compared to the consensus estimate of $105.75 million. During the same period in the previous year, the business posted $0.25 earnings per share. The business’s revenue for the quarter was down 28.0% compared to the same quarter last year. On average, analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.56 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IRWD has been the topic of a number of analyst reports. Piper Sandler increased their price objective on shares of Ironwood Pharmaceuticals from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Friday, February 16th. Craig Hallum dropped their price target on shares of Ironwood Pharmaceuticals from $18.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday, May 10th. StockNews.com downgraded Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, April 6th. Finally, Wells Fargo & Company decreased their price objective on Ironwood Pharmaceuticals from $20.00 to $14.00 and set an “overweight” rating for the company in a report on Friday, March 1st. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $18.40.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Signaturefd LLC boosted its position in shares of Ironwood Pharmaceuticals by 61.4% during the 4th quarter. Signaturefd LLC now owns 2,160 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 822 shares in the last quarter. Daiwa Securities Group Inc. raised its holdings in shares of Ironwood Pharmaceuticals by 331.6% in the 4th quarter. Daiwa Securities Group Inc. now owns 2,473 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,900 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in Ironwood Pharmaceuticals by 152.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 2,645 shares during the last quarter. Headlands Technologies LLC boosted its holdings in Ironwood Pharmaceuticals by 396.5% during the third quarter. Headlands Technologies LLC now owns 6,737 shares of the biotechnology company’s stock worth $65,000 after buying an additional 5,380 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in Ironwood Pharmaceuticals in the first quarter worth approximately $91,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.